EDSON ABDALA

(Fonte: Lattes)
Índice h a partir de 2011
23
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina - Docente
LIM/37 - Laboratório de Transplante e Cirurgia de Fígado, Hospital das Clínicas, Faculdade de Medicina
LIM/47 - Laboratório de Hepatologia por Vírus, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Categoria: meeting abstract ×

Resultados de Busca

Agora exibindo 1 - 10 de 12
  • conferenceObject
    The Influence of Antifungal Prophylaxis in Invasive Fungal Infections in Liver Transplantation
    (2015) SONG, Alice T. W.; ALMEIDA JUNIOR, Joao N.; MAU, Luciana B.; FREIRE, Maristela; PROENCA, Adriana; HADDAD, Luciana; D'ALBUQUERQUE, Luiz A. C.; ABDALA, Edson
  • conferenceObject
    Cardiovascular risk and coronary artery calcium score after liver transplantation: study at fouth year
    (2017) LINHARES, L. M.; OLIVEIRA, C. P.; ALVARES-DA-SILVA, M. R.; STEFANO, J. T.; GEBRIM, E. M.; BARBEIRO, H. V.; BARBEIRO, D. F.; TERRABUIO, D. R.; ABDALA, E.; SORIANO, F. G.; CARRILHO, F. J.; FARIAS, A. Q.; AUGUSTO, L.; ALBUQUERQUE, C. D'
  • conferenceObject
    The Worth of Surveillance for Vancomycin-Resistant Enterococci in the Hematology-Oncology Unit
    (2014) BELLESSO, Marcelo; ABDALA, Edson; PEREIRA, Juliana; SANTUCCI, Rodrigo; IBRAHIM, Karim Yaqub; FREIRE, Maristela Pinheiro; FRATELLI, Lumena Vaz Carvalho; MARQUES, Patricia Andrea Crippa
  • conferenceObject
    Predictive factors of survival in liver retransplantation for hepatitis C recurrence: the importance of HCV therapy
    (2013) SONG, Alice T.; SOBESKY, Rodolphe; VINAIXA, Carmen; DUMORTIER, Jerome; RADENNE, Sylvie; DURAND, Francois; CALMUS, Yvon; ROUSSEAU, Geraldine; LATOURNERIE, Marianne; FERAY, Cyrille; DELVART, Valerie; ROCHE, Bruno; HAIM-BOUKOZA, Stephanie; ROQUE-AFONSO, Anne-Marie; CASTAING, Denis X.; ABDALA, Edson; DUCLOS-VALLEE, Jean-Charles; BERENGUER, Marina; SAMUEL, Didier
  • conferenceObject
    IMMUNODIAGNOSIS OF STRONGYLOIDES STERCORALIS INFECTION IN CANDIDATE PATIENTS FOR TRANSPLANTATION
    (2015) GOTTARDI, Maiara; PAULA, Fabiana M.; CORRAL, Marcelo A.; MEISEL, Dirce M.; COSTA, Silvia F.; ABDALA, Edson; PIERROTTI, Ligia; CHIEFFI, Pedro Paulo; GRYSCHEK, Ronaldo C.
  • conferenceObject
    Predictive Factors of Survival and Prognostic Score Validation in Liver Retransplantation for Severe Hepatitis C Recurrence: The Importance of HCV Therapy before and after Retransplantation
    (2013) SONG, A. T. W.; SOBESKY, R.; VINAIXA, C.; DUMORTIER, J.; RADENNE, S.; ROUSSEAU, G.; DURAND, F.; DELVART, V.; ROCHE, B.; HAIM-BOUKOBZA, S.; VIBERT, E.; CASTAING, D.; ABDALA, E.; BERENGUER, M.; DUCLOS-VALLEE, J. C.; SAMUEL, D.
    Indications and results of retransplantation (RT) for HCV recurrence are debatable. Recently, a Swiss group proposed the Andres RT survival score specifically designed for HCV-positive patients. Aim: To identify risk factors associated with survival in RT patients for HCV recurrence and to evaluate the Andres score. Methods: Retrospective and multicentric study to determine prognostic factors of survival. A cohort of patients presenting F4 or FCH without RT was also analysed. Results: From 1984 to 2012, 77 patients were retransplanted for HCV recurrence. 79% were males, mean age 53±9 years, genotype 1 in 74%, 58.4% received HCV therapy preRT. MELD at RT was 24±8 and 25.7% received steroid boluses post-RT. Overall, 3, 5 and 10-year survival rates were 63%, 55%, and 52% respectively. 79% had an Andres score >40 (n=48). Andres score underestimated survival, as in their cohort, those with a score >40 presented a 5y survival of 27%. 42 patients with F4 or FCH post-transplant presenting decompensation presented survival rates of 15%, 7% and 0% at 3, 5 and 10 ys (p<0.0001). In univariate analysis, factors associated with better survival post-RT were: male gender (p=0.08), non-genotype 1 (p=0.06), interval between 1st transplant and acute hepatitis (p=0.006), undetectable viremia preRT (p=0.04), tacrolimus post-RT (p=0.08), HCV therapy post-RT (p=0.002), preRT bilirubin (p=0.04), RT donor age (p=0.06), recipient age at 1st transplant (p=0.06), interval between 1st transplant and RT (p=0.05), lower Andres score (p=0.006). In multivariate analysis, factors associated with survival were: HCV therapy post-RT (p=0.01), recipient age at 1st transplant (p=0.03), RT donor age (p=0.03), pre-RT bilirubin (p=0.01), non-genotype 1 (p=0.02). Conclusions: HCV therapy post-RT, non-genotype 1, recipient and RT donor age represent major prognostic factors for RT.
  • conferenceObject
    Evidence of Hepatitis E Virus Infection in Liver Transplant Recipients from Brazil
    (2013) GOMES-GOUVEA, Michele S.; FERREIRA, Ariana C.; FEITOZA, Bruna; PESSOA, Mario G.; ABDALA, Edson; TERRABUIO, Deborah R.; MORAES, Adriano C.; BONAZZI, Patricia R.; D'ALBUQUERQUE, Luiz C.; CARRILHO, Flair J.; PINHO, Joao R.
  • conferenceObject
    PREDICTIVE FACTORS OF SURVIVAL AND PROGNOSTIC SCORE VALIDATION IN LIVER RETRANSPLANTATION FOR SEVERE HEPATITIS C RECURRENCE: THE IMPORTANCE OF HCV THERAPY BEFORE AND AFTER RETRANSPLANTATION
    (2013) SONG, A. T. W.; SOBESKY, R.; VINAIXA, C.; DUMORTIER, J.; RADENNE, S.; ROUSSEAU, G.; DELVART, V.; HAIM-BOUKOBZA, S.; ROQUE-AFONSO, A. -M.; ROCHE, B.; VIBERT, E.; CASTAING, D.; ABDALA, E.; BERENGUER, M.; DUCLOS-VALLEE, J. -C.; SAMUEL, D.
    Background: Liver retransplantation (RT) is the only therapeutic option for irreversible failure of the liver graft. Indications and results of RT for HCV-related disease are debatable. Recently, a Swiss group proposed a retransplantation survival score specifically designed for HCV-positive patients in order to aid in candidate selection. Aim: To identify risk factors associated with survival in patients retransplanted for HCV-related disease, and to evaluate the Andres survival score in this population. Methods: We have conducted a retrospective and multicentric study (4 centers) to determine prognostic factors of 3, 5 and 10-year patient survival. Results: Sixty-seven patients were retransplanted for HCV recurrence, from January 1984 until September 2012. Baseline characteristics were: 76.1% males, mean age 53 ± 9 years, genotype 1 in 44 (75.9%), 19 (29.7%) received corticosteroid boluses after RT, 38 (56.7%) received HCV therapy before RT, and of these, 7 (10.4%) presented SVR. Mean MELD score at RT was 24 ± 8. Overall, 3, 5 and 10-year survival rates were 65%, 57%, and 53% respectively. Among 37 patients in whom data for Andres score application was available, 26 (70.3%) had a score above 40. For patients with an Andres score below 40 and above 40, 5-year survival was 81% and 47%, respectively. In univariate analysis, factors potentially associated with better survival were: female gender (p=0.04), deceased donor versus living or domino (p=0.02), undetectable HCV viremia before RT (p=0.059), tacrolimus-based immunosupression after RT (p=0.047), antiviral treatment after RT (p=0.01), lower BMI (p=0.01), younger age at first transplantation (p=0.027), longer interval between first transplantation and RT (p=0.037) and Andres score below 40 (p=0.098). In multivariate analysis, factors associated with survival were: undetectable HCV- RNA before RT (p=0.044, RR=8.42), lower BMI at RT (p=0.009, RR=1.13), and antiviral treatment after RT (p=0.015, RR=0.33). Conclusions: Overall 3, 5 and 10-year survival rates were 65%, 57%, and 53% respectively. Anti-HCV therapy before and after RT represents a major prognostic factor, and patients that received therapy before RT or are potentially able to receive it after RT, may have good prognosis. In our cohort, Andres score underestimated survival rates.
  • conferenceObject
    Toxoplasmosis Post-Kidney Or Liver Transplantation: A Serie of Cases
    (2015) PIERROTTI, L.; SALLES, R.; RYTHOLZ, M.; AZEVEDO, L.; SONG, A.; D'ALBUQUERQUE, L.; DAVID-NETO, E.; NAHAS, W.; ABDALA, E.
  • conferenceObject
    CORONARY ARTERY CALCIUM SCORE AND FRAMINGHAM SCORE IN EVALUATION OF CARDIOVASCULAR RISK AFTER LIVER TRANSPLANTATION
    (2016) CARONE, L.; OLIVEIRA, C. P.; ALVARES-DA-SILVA, M. R.; STEFANO, J. T.; TERRABUIO, D. R. B.; ABDALA, E.; CARRILHO, F. J.; FARIAS, A. Q.; D'ALBUQUERQUE, L. A. C.